Morgan Stanley lowered the firm’s price target on NeoGenomics (NEO) to $10 from $17 and keeps an Equal Weight rating on the shares. The company’s Q1 miss was primarily driven by lower non-clinical revenue and lower than expected average unit price, says the analyst, who sees “more questions than answers” following the company’s quarterly report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NEO: